RhumbLine Advisers’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $255K | Buy |
|
|||||
|
2025
Q2 | $112K | Buy |
|
|||||
|
2025
Q1 | $120K | Sell |
|
|||||
|
2024
Q4 | $214K | Buy |
|
|||||
|
2024
Q3 | $155K | Sell |
|
|||||
|
2024
Q2 | $268K | Buy |
|
|||||
|
2024
Q1 | $310K | Buy |
|
|||||
|
2023
Q4 | $415K | Sell |
|
|||||
|
2023
Q3 | $477K | Sell |
|
|||||
|
2023
Q2 | $944K | Buy |
|
|||||
|
2023
Q1 | $1.41M | Buy |
|
|||||
|
2022
Q4 | $1.55M | Buy |
|
|||||
|
2022
Q3 | $1.8M | Buy |
|
|||||
|
2022
Q2 | $1.3M | Buy |
|
|||||
|
2022
Q1 | $2.13M | Buy |
|
|||||
|
2021
Q4 | $2.49M | Sell |
|
|||||
|
2021
Q3 | $2.54M | Sell |
|
|||||
|
2021
Q2 | $2.56M | Sell |
|
|||||
|
2021
Q1 | $2.75M | Buy |
|
|||||
|
2020
Q4 | $3.08M | Buy |
|
|||||
|
2020
Q3 | $3.13M | Sell |
|
|||||
|
2020
Q2 | $3.25M | Buy |
|
|||||
|
2020
Q1 | $1.66M | Sell |
|
|||||
|
2019
Q4 | $1.91M | Buy |
|
|||||
|
2019
Q3 | $2.07M | Sell |
|
|||||
|
2019
Q2 | $2.35M | Buy |
|
|||||
|
2019
Q1 | $1.22M | Buy |
|
|||||
|
2018
Q4 | $618K | Buy |
|
|||||
|
2018
Q3 | $721K | Sell |
|
|||||
|
2018
Q2 | $631K | Buy |
|
|||||
|
2018
Q1 | $393K | Sell |
|
|||||
|
2017
Q4 | $319K | Sell |
|
|||||
|
2017
Q3 | $571K | Buy |
|
|||||
|
2017
Q2 | $607K | Buy |
|
|||||
|
2017
Q1 | $765K | Buy |
|
|||||
|
2016
Q4 | $907K | Buy |
|
|||||
|
2016
Q3 | $797K | Buy |
|
|||||
|
2016
Q2 | $483K | Buy |
|
|||||
|
2016
Q1 | $479K | Buy |
|
|||||
|
2015
Q4 | $516K | Buy |
|
|||||
|
2015
Q3 | $416K | Buy |
|
|||||
|
2015
Q2 | $575K | Buy |
|